Discounted Cash Flow (DCF) Analysis Unlevered

ASLAN Pharmaceuticals Limited (ASLN)

$ 1.3
-0.14 (-9.72%)
Stock DCF: - | 1.3 | undervalue

Operating Data

Year
A/P
2016
Actual
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 11.49---------
Revenue (%)
EBITDA -8.58---------
EBITDA (%)
EBIT -8.66---------
EBIT (%)
Depreciation 0.08---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash 51.56---------
Total Cash (%)
Account Receivables 1.29---------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 2.27---------
Accounts Payable (%)
Capital Expenditure -0.45---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.3
Beta 2.389
Diluted Shares Outstanding 38.45
Cost of Debt
Tax Rate 4.56
After-tax Cost of Debt 6.27%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.708
Total Debt 18.97
Total Equity 49.98
Total Capital 68.95
Debt Weighting 27.52
Equity Weighting 72.48
Wacc

Build Up Free Cash

Year
A/P
2016
Actual
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 11.49---------
EBITDA -8.58---------
EBIT -8.66---------
Tax Rate 0.00%0.00%-0.03%-0.87%4.56%0.73%0.73%0.73%0.73%0.73%
EBIAT -8.66---------
Depreciation 0.08---------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0.45-0.31-23.08-0-0.01-----
UFCF -9.03---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 10.94
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 4.65
Equity Value -
Shares Outstanding 38.45
Equity Value Per Share -